Comparison between Gujarat Kidney IPO and Runwal Enterprises IPO.
Gujarat Kidney IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Runwal Enterprises IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Gujarat Kidney IPO is up to ₹250.80 Cr whereas the issue size of the Runwal Enterprises IPO is up to ₹1,000.00 Cr. The final issue price of Gujarat Kidney IPO is ₹114.00 per share and of Runwal Enterprises IPO is .
| Gujarat Kidney IPO | Runwal Enterprises IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹2 per share |
| Issue Price (Lower) | ₹108.00 per share | |
| Issue Price (Upper) | ₹114.00 per share | |
| Issue Price (Final) | ₹114.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 128 shares | |
| Fresh Issue Size | 2,20,00,000 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹250.80 Cr | up to ₹1,000.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 2,20,00,000 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹250.80 Cr | up to ₹1,000.00 Cr |
Gujarat Kidney IPO opens on Dec 22, 2025, while Runwal Enterprises IPO opens on . The closing date of Gujarat Kidney IPO and Runwal Enterprises IPO is Dec 24, 2025, and , respectively.
| Gujarat Kidney IPO | Runwal Enterprises IPO | |
|---|---|---|
| Anchor Bid Date | Dec 19, 2025 | |
| Issue Open | Dec 22, 2025 | |
| Issue Close | Dec 24, 2025 | |
| Basis Of Allotment (Tentative) | Dec 26, 2025 | |
| Initiation of Refunds (Tentative) | Dec 29, 2025 | |
| Credit of Share (Tentative) | Dec 29, 2025 | |
| Listing date (Tentative) | Dec 30, 2025 | |
| Anchor Lockin End date 1 | Jan 24, 2026 | |
| Anchor Lockin End date 2 | Mar 25, 2026 |
Gujarat Kidney IPO P/E ratio is 61.62, as compared to Runwal Enterprises IPO P/E ratio of .
| Gujarat Kidney IPO | Runwal Enterprises IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Gujarat Kidney & Super Speciality Ltd.'s revenue increased by 637% and profit after tax (PAT) rose by 454% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.1 | 87.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 71.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 61.62 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹898.81 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 36.61% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 37.65% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹1.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 36.61% | 26.69% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Gujarat Kidney IPO Retail Individual Investors (RII) are offered 22,00,000 shares while in Runwal Enterprises IPO retail investors are offered 22,00,000 shares. Qualified Institutional Buyers (QIB) are offered 77,26,880 shares in Gujarat Kidney IPO and in Runwal Enterprises IPO.
| Gujarat Kidney IPO | Runwal Enterprises IPO | |
|---|---|---|
| Anchor Investor Reservation | 87,73,120 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 77,26,880 shares | |
| NII | 33,00,000 shares | |
| RII | 22,00,000 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 2,20,00,000 shares |
Gujarat Kidney IPO subscribed 5.21x in total, whereas Runwal Enterprises IPO subscribed .
| Gujarat Kidney IPO | Runwal Enterprises IPO | |
|---|---|---|
| QIB (times) | 1.06x | |
| NII (times) | 5.73x | |
| Big NII (times) | 5.25x | |
| Small NII (times) | 6.68x | |
| RII (times) | 19.04x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 5.21x |
